Hopper Jonathan Mark 4

4 · Vericel Corp · Filed Jun 4, 2026

AI-generated summary of this filing

Updated Jun 4, 2026

Vericel (VCEL) CMO Jonathan Hopper Exercises Options, Sells Shares

What Happened

Jonathan Mark Hopper, Chief Medical Officer of Vericel (VCEL), exercised/converted derivative awards and sold shares on June 2, 2026. The filing shows he acquired 4,375 shares by exercising a derivative at $16.66 per share (cost $72,888) and sold 4,375 shares in an open-market sale at $35.00 per share for gross proceeds of $153,125. The filing also reports a conversion/exercise of 4,375 shares with a reported $0 exercise price (reported as a derivative acquisition).

Key Details

Transaction date: 2026-06-02 (reported on Form 4 filed 2026-06-04).
Exercise/Acquisitions: 4,375 shares @ $16.66 (total reported cost $72,888) and 4,375 shares @ $0 (derivative conversion).
Sale: 4,375 shares @ $35.00 for $153,125 (open market sale).
Shares owned after transaction: Not specified in the provided excerpt of the filing.
Notable footnotes:
- F2: The sale was effected automatically under a Rule 10b5-1 trading plan adopted May 30, 2025.
- F1 and F3: Footnotes reference shares acquired under the company ESPP and the vesting/exercise schedule for options (options representing rights to 26,000 shares vested in quarterly installments starting May 6, 2019).
Filing timeliness: Form 4 was filed two days after the transaction date (appears timely).

Context

Because the exercise/acquisition and sale involved the same number of shares on the same date, this effectively functioned as a cashless exercise (exercise/convert then immediate sale), which is common for executives realizing value from vested awards.
The sale was pre-planned under a 10b5-1 program, meaning the disposition followed an automated trading plan rather than an on-the-spot decision.

Form 4

Period: 2026-06-02

Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-06-02$16.66/sh+4,375$72,888→ 80,128 total
Sale
Common Stock
[F2][F1]
2026-06-02$35.00/sh−4,375$153,125→ 75,753 total
Exercise/Conversion
Stock Option (Right to Buy)
[F3]
2026-06-02+4,375→ 1,625 total
Exercise: $16.66Exp: 2029-02-06→ Common Stock (4,375 underlying)

Footnotes (3)

[F1]These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
[F2]The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025.
[F3]These options, representing the right to purchase 26,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 6, 2019, which was one quarter after the date on which the option was granted.

Signature

/s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper|2026-06-04

1 file